Symbiotec Pharmalab IPO GMP - Day 3: GMP ₹340 (34.41%) & 5.60x Subscribed

Key takeaways:
- Symbiotec Pharmalab IPO is a book-built issue of ₹1,757 crore, comprising a fresh issue (₹150 crore) and an OFS (₹1,607 crore).
- The price band is set at ₹938 to ₹988 per share with a minimum retail investment amount of ₹14,820 for 15 shares.
- The issue was well received and achieved an overall subscription of 5.60 times by the end of the third day.
- The current GMP is an impressive ₹340, which translates to an estimated listing price of ₹1,328 and a listing premium of about 34.41%.
- The company is a global leader in the production volume of corticosteroid and steroidal hormone APIs.
The company holds a leading market share in the international market for corticosteroid and steroidal hormone active pharmaceutical ingredients (APIs).
The public issue of ₹1,757 crore witnessed a significant surge in demand on Day 3 after a steady start on the first two days. Overall subscription was 5.60 times, driven by strong demand from retail and non-institutional buyers. Moreover, Grey Market Premium (GMP) is at ₹340.
This public issue is a combination of a fresh equity issuance of ₹150 crore and an offer for sale (OFS) of ₹1,607 crore by the current promoters and shareholders. The net proceeds from the fresh issue will be used to prepay/repay outstanding borrowings and for general corporate purposes. Here we will discuss in detail the Day 3 bidding of the Symbiotec Pharmalab IPO.
Key dates of Symbiotec Pharmalab IPO
The public bidding of the Symbiotec Pharmalab IPO began on Monday, August 24, 2026, and will close tomorrow, Thursday, August 27, 2026. The allotment of shares is likely to be finalised on Friday, August 28, 2026. The company will start refunds and unblock bank mandates from Monday, August 31, 2026, for investors who are not allotted shares.
The successful bidders will get the equity shares credited to their demat accounts on the same day. Symbiotec Pharmalab is gearing up for its stock market debut, with its shares tentatively scheduled to list on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on Tuesday, September 1, 2026.
The price band for the issue is fixed between ₹938 and ₹988 per share. Retail investors can subscribe to a minimum of 1 lot of 15 shares, with a minimum investment of ₹14,820. MUFG Intime India Pvt. Ltd. is the registrar for the issue, while JM Financial Ltd. is the book-running lead manager.
About Symbiotec Pharmalab
Symbiotec Pharmalab Limited was incorporated in 2002 and is a research-oriented pharmaceutical and biotechnology company involved in the development and production of active pharmaceutical ingredients (APIs), complex injectables and biotechnology-based products. The company specialises in corticosteroids and steroidal hormones, and serves regulated pharmaceutical markets globally.
Symbiotec has a vertically integrated manufacturing network in Madhya Pradesh, with dedicated production, fermentation and injectable manufacturing facilities. The company has its own highly successful product line and also offers contract development and manufacturing (CDMO) services to pharmaceutical and nutraceutical clients worldwide, with multiple international regulatory certifications.
The company has shown consistent financial growth in the last few years. Symbiotec Pharmalab's total income increased from ₹755.98 crore in FY25 to ₹872.26 crore in FY26. Moreover, its profit after tax (PAT) also rose from ₹96.79 crore in FY25 to ₹109.90 crore in FY26.
Day 3 subscription status and GMP
On Day 3, the Symbiotec Pharmalab IPO achieved an overall subscription of 5.60 times. Momentum was largely led by Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs), who continued to show strong interest ahead of the final day.
The Non-Institutional Investors (NII) segment led the way, oversubscribing their quota allocation by 12.84 times. The Retail Individual Investors (RIIs) segment also saw good activity with subscriptions of 5.35 times. Qualified Institutional Buyers (QIBs) showed a measured response, subscribing 0.62 times. The IPO has an employee quota as well, which was subscribed by 6.22 times.
Grey Market sentiment remains positive on Day 3 and currently stands at ₹340. This current GMP, at the upper price band of ₹988, indicates a healthy estimated listing price of ₹1,328 per share. This means allottees could see a potential listing gain of 34.41%.
The IPO is scheduled to close tomorrow, and all eyes will be on the final-day subscription numbers to see whether institutional buyers bid aggressively, boosting subscriptions and stabilising the GMP ahead of its listing on September 1, 2026.












